Dynavax Technologies Corporation (DVAX) saw its loss narrow to $21.74 million, or $0.56 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $26.86 million, or $0.70 a share. Revenue during the quarter surged 964.53 percent to $7.29 million from $0.68 million in the previous year period.
Operating loss for the quarter was $19.32 million, compared with an operating loss of $26.95 million in the previous year period.
"We are pleased with the continued progress of our immuno-oncology portfolio during 2016 and the recent promising clinical results from our combination trial in melanoma," said Eddie Gray, chief executive officer for Dynavax. "With the expansion of SD-101 into Phase 2 in both melanoma and head and neck cancer this quarter, our marketing application for HEPLISAV-B under review by the FDA and our strong cash balance, we are in position to deliver key outcomes for several programs during 2017."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
